ArticleLiver cancer2022

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.

Masatoshi KudoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.